Publication:


abstract

OBJECTIVE:

In vitro evidence suggests insulin glargine promotes tumors; observational human studies are conflicting. We aimed to expand understanding of this potential treatment risk.

RESEARCH DESIGN AND METHODS:

This retrospective cohort study of type 2 diabetic patients >68 years old used Medicare inpatient, outpatient (2003-2008), and prescription data (2006-2008). Adjusting for patient characteristics, dose, and metformin use, Cox models yielded hazard ratios (HRs) for incident cancer (breast, prostate, pancreas, colon, any site) associated with three forms of insulin: nonglargine, glargine, or glargine plus nonglargine (combination).

RESULTS:

Overall, 81,681 patients were followed for a mean of 23.1 months. Mean age was 77.4 years. Treatment group distribution was 20.7% glargine, 60.5% nonglargine, 18.7% combination insulin. We observed 5,466 incident cancers; crude rates did not vary by treatment group. In fully adjusted models, nonglargine use was the referent; glargine was not associated with significant increased risk of any cancer measure. In secondary analyses including only the top quartile of daily insulin dose patients, glargine was not associated with any cancer risk difference; combination insulin was associated with higher breast cancer risk (HR 1.75 [95% CI 1.10-2.78]) and lower colon cancer risk (0.33 [0.13-0.80]). In age-stratified analyses of highest-dose users, combination insulin conferred a higher risk of breast cancer in those ≤75 years old (2.87 [1.45-1.59]).

CONCLUSIONS:

The general lack of association between glargine-only use and cancer is reassuring. Breast cancer risk associated with high-dose combination insulin in secondary analyses could result from multiple comparisons, residual confounding, or true association; Further research is warranted.

Related Articles
Long-term effects of insulin glargine on the risk of breast cancer.
Diabetologia. 2011
Long-term effects of insulin glargine on the risk of breast cancer.
Suissa S, Azoulay L, Dell'Aniello S, Evans M, Vora J, Pollak M. Diabetologia. 2011 Sep; 54(9):2254-62. Epub 2011 May 26.
Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group.
Diabetologia. 2009
Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group.
Colhoun HM, SDRN Epidemiology Group. Diabetologia. 2009 Sep; 52(9):1755-65. Epub 2009 Jul 15.
Cancer risk associated with insulin glargine among adult type 2 diabetes patients--a nationwide cohort study.
PLoS One. 2011
Cancer risk associated with insulin glargine among adult type 2 diabetes patients--a nationwide cohort study.
Chang CH, Toh S, Lin JW, Chen ST, Kuo CW, Chuang LM, Lai MS. PLoS One. 2011; 6(6):e21368. Epub 2011 Jun 27.
Review Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
Pharmacoeconomics. 2004
Review Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
Plosker GL, Figgitt DP. Pharmacoeconomics. 2004; 22(6):389-411.
Review Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus.
Cochrane Database Syst Rev. 2007
Review Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus.
Horvath K, Jeitler K, Berghold A, Ebrahim SH, Gratzer TW, Plank J, Kaiser T, Pieber TR, Siebenhofer A. Cochrane Database Syst Rev. 2007 Apr 18; (2):CD005613. Epub 2007 Apr 18.
Cancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis.
PLoS One. 2012
Cancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis.
Noto H, Goto A, Tsujimoto T, Noda M. PLoS One. 2012; 7(3):e33411. Epub 2012 Mar 20.
Risk of cancer in patients on insulin glargine and other insulin analogues in comparison with those on human insulin: results from a large population-based follow-up study.
Diabetologia. 2012
Risk of cancer in patients on insulin glargine and other insulin analogues in comparison with those on human insulin: results from a large population-based follow-up study.
Ruiter R, Visser LE, van Herk-Sukel MP, Coebergh JW, Haak HR, Geelhoed-Duijvestijn PH, Straus SM, Herings RM, Stricker BH. Diabetologia. 2012 Jan; 55(1):51-62. Epub 2011 Sep 29.